238 related articles for article (PubMed ID: 23906044)
1. N-substituted piperazinopyridylsteroid derivatives as abiraterone analogues inhibit growth and induce pro-apoptosis in human hormone-independent prostate cancer cell lines.
Brossard D; Zhang Y; Haider SM; Sgobba M; Khalid M; Legay R; Duterque-Coquillaud M; Galera P; Rault S; Dallemagne P; Moslemi S; El Kihel L
Chem Biol Drug Des; 2013 Nov; 82(5):620-9. PubMed ID: 23906044
[TBL] [Abstract][Full Text] [Related]
2. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
DeVore NM; Scott EE
Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Pinto-Bazurco Mendieta MA; Negri M; Jagusch C; Müller-Vieira U; Lauterbach T; Hartmann RW
J Med Chem; 2008 Aug; 51(16):5009-18. PubMed ID: 18672868
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of new steroidal pyridines as potential anti-prostate cancer agents.
Shi YK; Wang B; Shi XL; Zhao YD; Yu B; Liu HM
Eur J Med Chem; 2018 Feb; 145():11-22. PubMed ID: 29310026
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.
Nikolić AR; Petri ET; Klisurić OR; Ćelić AS; Jakimov DS; Djurendić EA; Penov Gaši KM; Sakač MN
Bioorg Med Chem; 2015 Feb; 23(4):703-11. PubMed ID: 25619894
[TBL] [Abstract][Full Text] [Related]
6. A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone.
Garrido M; Peng HM; Yoshimoto FK; Upadhyay SK; Bratoeff E; Auchus RJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():1-10. PubMed ID: 24508512
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antiproliferative activity evaluation of steroidal imidazo[1,2-a]pyridines.
Rassokhina IV; Volkova YA; Kozlov AS; Scherbakov AM; Andreeva OE; Shirinian VZ; Zavarzin IV
Steroids; 2016 Sep; 113():29-37. PubMed ID: 27263438
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, 17α-hydroxylase-C
Banday AH; Shameem SA; Banday JA; Ganaie BA
Anticancer Agents Med Chem; 2018; 18(13):1919-1926. PubMed ID: 29697032
[TBL] [Abstract][Full Text] [Related]
9. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors.
Jarman M; Barrie SE; Llera JM
J Med Chem; 1998 Dec; 41(27):5375-81. PubMed ID: 9876107
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of new steroidal imidazo [1,2-a] pyridines: DNA binding studies, cleavage activity and in vitro cytotoxicity.
Dar AM; Shamsuzzaman ; Gatoo MA
Steroids; 2015 Dec; 104():163-75. PubMed ID: 26433147
[TBL] [Abstract][Full Text] [Related]
11. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
[TBL] [Abstract][Full Text] [Related]
12. [Advances in the study of steroidal inhibitors of cytochrome P45017alpha].
Du JJ; Chen HL; Li YC
Yao Xue Xue Bao; 2013 Jan; 48(1):25-31. PubMed ID: 23600137
[TBL] [Abstract][Full Text] [Related]
13. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
Malikova J; Brixius-Anderko S; Udhane SS; Parween S; Dick B; Bernhardt R; Pandey AV
J Steroid Biochem Mol Biol; 2017 Nov; 174():192-200. PubMed ID: 28893623
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and anticancer activity of novel C6-piperazine substituted purine steroid-nucleosides analogues.
Huang LH; Xu HD; Yang ZY; Zheng YF; Liu HM
Steroids; 2014 Apr; 82():1-6. PubMed ID: 24378780
[TBL] [Abstract][Full Text] [Related]
15. Comparison of [17(20)E]-21-Norpregnene oxazolinyl and benzoxazolyl derivatives as inhibitors of CYP17A1 activity and prostate carcinoma cells growth.
Zolottsev VA; Tkachev YV; Latysheva AS; Kostin VA; Novikov RA; Timofeev VP; Morozevich GE; Kuzikov AV; Shumyantseva VV; Misharin AY
Steroids; 2018 Jan; 129():24-34. PubMed ID: 29183745
[TBL] [Abstract][Full Text] [Related]
16. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents.
Eilon GF; Gu J; Slater LM; Hara K; Jacobs JW
Cancer Chemother Pharmacol; 2000; 45(3):183-91. PubMed ID: 10663635
[TBL] [Abstract][Full Text] [Related]
17. Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer.
Bordeau BM; Ciulla DA; Callahan BP
ChemMedChem; 2016 Sep; 11(18):1983-6. PubMed ID: 27435344
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways.
Grossebrummel H; Peter T; Mandelkow R; Weiss M; Muzzio D; Zimmermann U; Walther R; Jensen F; Knabbe C; Zygmunt M; Burchardt M; Stope MB
Int J Oncol; 2016 Feb; 48(2):793-800. PubMed ID: 26648519
[TBL] [Abstract][Full Text] [Related]
19. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
[TBL] [Abstract][Full Text] [Related]
20. Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site.
Petrunak EM; Bart AG; Peng HM; Auchus RJ; Scott EE
J Biol Chem; 2023 Mar; 299(3):102999. PubMed ID: 36773804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
